Biohaven Ltd. (NYSE:BHVN) Shares Sold by Amundi

Amundi lowered its position in shares of Biohaven Ltd. (NYSE:BHVN) by 15.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 3,415 shares of the company’s stock after selling 613 shares during the quarter. Amundi’s holdings in Biohaven were worth $134,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Stifel Financial Corp lifted its holdings in shares of Biohaven by 0.4% in the 3rd quarter. Stifel Financial Corp now owns 6,509,261 shares of the company’s stock valued at $325,268,000 after buying an additional 28,684 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Biohaven by 5.6% in the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company’s stock valued at $311,142,000 after buying an additional 328,099 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Biohaven by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,714,612 shares of the company’s stock valued at $85,696,000 after buying an additional 44,174 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Biohaven by 745.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock valued at $74,969,000 after buying an additional 1,322,922 shares during the period. Finally, ARS Investment Partners LLC lifted its holdings in shares of Biohaven by 1.0% in the 4th quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company’s stock valued at $38,871,000 after buying an additional 10,473 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Trading Up 1.5 %

NYSE:BHVN opened at $28.61 on Friday. Biohaven Ltd. has a 12 month low of $26.80 and a 12 month high of $59.53. The stock has a 50 day moving average of $35.89 and a two-hundred day moving average of $41.60. The firm has a market cap of $2.92 billion, a P/E ratio of -3.06 and a beta of 1.27.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, research analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on BHVN shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. JPMorgan Chase & Co. cut their price target on Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Morgan Stanley cut their price target on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Deutsche Bank Aktiengesellschaft began coverage on Biohaven in a research note on Tuesday, February 11th. They issued a “buy” rating and a $65.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $54.00 price target on shares of Biohaven in a research note on Tuesday, March 4th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Biohaven presently has an average rating of “Buy” and an average price target of $63.15.

Insiders Place Their Bets

In related news, Director John W. Childs purchased 32,700 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the transaction, the director now directly owns 2,320,571 shares of the company’s stock, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.00% of the stock is owned by company insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.